Table 1.
Compound | RT * | λmax | [M-H] m/z | Content (%) | |||||
---|---|---|---|---|---|---|---|---|---|
min | nm | MS | MS/MS | 0 ppm 0 min | 10 ppm 10 min | 30 ppm 10 min | 50 ppm 10 min | ||
1 | p-coumaric acid | 2.73 | 309 | 163 | 119 | 0.06 | 0.30 | 0.34 | 0.25 |
2 | Caftaric acid | 2.96 | 288 sh. 327 | 311 | 179 | 0.15 | 0.19 | 0.30 | 0.17 |
3 | Feruloyl-caffeic acid | 3.15 | 288 sh. 322 | 367 | 193 | 0.12 | 0.14 | 0.21 | 0.09 |
4 | Unspecified caffeic derivative | 3.24 | 288 sh. 324 | 425 | 367 | 0.04 | 0.31 | 0.34 | 0.32 |
5 | Luteolin 6-C-arabinoside-8-C-glucoside | 3.38 | 274. 341 | 579 | 447. 285 | 1.25 | 0.92 | 0.90 | 0.91 |
6 | Isoscoparin 7-O-glucoside | 3.51 | 276. 333 | 623 | 461. 299 | 0.22 | 0.32 | 0.36 | 0.04 |
7 | Isoorientin 7-O-glucoside | 3.75 | 269. 347 | 609 | 447. 285 | 1.21 | 1.18 | 0.91 | 1.42 |
8 | Isovitexin 7-O-glucoside | 3.88 | 269. 331 | 593 | 431 | 81.72 | 79.42 | 82.06 | 82.31 |
9 | Isovitexin 7-O-(6″-p-coumaroyl)-glucoside | 3.98 | 271. 324 | 739 | 593 | 1.49 | 2.69 | 1.82 | 2.05 |
10 | Isovitexin | 4.18 | 270. 338 | 431 | 269 | 0.52 | 0.03 | 0.20 | 0.35 |
11 | Isoorientin 7-O-(6″-sinapoyl)-glucoside | 4.57 | 271. 338 | 815 | 447 | 0.43 | 0.25 | 0.37 | 0.22 |
12 | Isoorientin 7-O-(6″-feruloyl)-glucoside | 4.72 | 271. 338 | 785 | 447 | 0.40 | 0.05 | 0.09 | 0.12 |
13 | Isovitexin 7-O-(6″-sinapoyl)-glucoside | 5.00 | 271. 334 | 799 | 431 | 6.33 | 8.86 | 7.42 | 6.61 |
14 | Isovitexin 7-O-(6″-sinapoyl)-glucoside-4′-O-glucoside | 5.11 | 270. 338 | 961 | 799. 593 | 0.51 | 0.37 | 0.18 | 0.11 |
15 | Isovitexin 7-O-(6″-feruloyl)-glucoside | 5.21 | 271. 331 | 769 | 431 | 4.71 | 4.48 | 4.04 | 4.50 |
16 | Apigenin 6-C-arabinoside-8-C-glucoside | 5.35 | 269. 329 | 563 | 443 | 0.87 | 0.51 | 0.47 | 0.54 |
* RT—retention time; sh = shoulder peak; ±SD and n = 3; FD. Note. Differences in results between the dose of ozone are indicated by different capital letters. difference at significant level α < 0.05.